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Abstract
Cancer cells can live and grow if they succeed in creating a favorable niche that often includes elements from the immune
system. While T lymphocytes play an important role in the host response to tumor growth, the mechanism of their
trafficking to the tumor remains poorly understood. We show here that T lymphocytes consistently infiltrate the primary
brain cancer, medulloblastoma. We demonstrate, both in vitro and in vivo, that these T lymphocytes are attracted to tumor
deposits only after the tumor cells have interacted with tumor vascular endothelium. Macrophage Migration Inhibitory
Factor (MIF)’’ is the key chemokine molecule secreted by tumor cells which induces the tumor vascular endothelial cells to
secrete the potent T lymphocyte attractant ‘‘Regulated upon Activation, Normal T-cell Expressed, and Secreted (RANTES).’’
This in turn creates a chemotactic gradient for RANTES-receptor bearing T lymphocytes. Manipulation of this pathway could
have important therapeutic implications.
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Introduction
Growing evidence indicates that cancer cells can only live and
grow if they succeed in creating a niche that favors their survival
and progression. [1] This microenvironment often includes
vascular endothelial cells, supporting stromal cells as well as
elements from the immune system. [2–5] T lymphocytes constitute
one of the most important effector mechanisms of antitumor
immunity and often contribute to the tumor microenvironment
and their role remains controversial. [6] T lymphocytic infiltrates
have been correlated with antitumor immunity and favorable
outcomes in a number of tumors. [6–10] Other reports
demonstrated the facilitative role of infiltrating T lymphocytes to
the survival and progression of tumor cells. [11–13] These
observations point out to the potential duality of the role of T
lymphocytes in the tumor microenvironment: possibly attempting
to cordon the tumor progression but also sustaining the tumor
niche.
While there is substantial knowledge about the sequence of
events creating the signals that drive leukocyte infiltration in
models of inflammation and autoimmune disease, [14–24] little is
known about the mechanistic events that attract T lymphocytes to
the tumor microenvironment. Decoding such events would
increase our understanding of the interaction between the tumor
cells and tumor infiltrating T lymphocytes and help develop
strategies to enhance or block this crosstalk. Growing evidence
supports the essential and complex role of the vascular
endothelium in tumor biology and cancer progression. [25–27]
It is now evident that the interactions between vascular endothelial
cells and the tumor microenvironment may regulate tumor
progression in a tumor-type-specific manner. [25]
We show here, using medulloblastoma as a model, that T
lymphocytes may only be attracted to tumor deposits if the tumor
cells have interacted with the tumor vascular endothelium.
Macrophage Migration Inhibitory Factor (MIF)’’ is the key
primary chemokine molecule secreted by tumor cells which
induces the potent T lymphocyte attractant ‘‘Regulated upon
Activation, Normal T-cell Expressed, and Secreted (RANTES)’’
from endothelial cells, which in turn creates a chemotactic
gradient for RANTES-receptor bearing T lymphocytes. Manip-
ulation of this pathway could have important therapeutic
implications.
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T lymphocytes consistently infiltrate primary
medulloblastoma
T lymphocytes constitute one of the most important effector
mechanisms of anti-tumor-immunity and often contribute to the
tumor microenvironment. It is well established that T lymphocytic
infiltrates are present in tumors outside the neuraxis, where they
can have tumor inhibitory or promoting effects. [6–13] In
contrast, less is known about these infiltrates in the context brain
tumors. We therefore opted to study this in medulloblastoma, the
most common pediatric brain tumor. We examined a series of
primary medulloblastoma and found a T lymphocyte infiltration
in 20 of 20 tumors examined using immunohistochemistry (IHC)
for CD3. The degree of the T lymphocyte infiltrate varied between
individual tumors and ranged between a modest perivascular
pattern (#1%; 15 of 20 tumors); moderate perivascular infiltration
with varying degrees of parenchymal spill (.1–10%; 4 of 20
tumors) to a uniform heavy perivascular and parenchymal
infiltration (.10%; 1 of 20 tumors). Similarly, tumor sections
from the same subjects were stained for CD8 using IHC and
showed similar degrees and patterns of infiltration (Figure 1).
T lymphocytes migrate and localize to distant tumor
deposits in the brain
We hypothesized that these infiltrates result from an innate
avidity of T cells to the tumor cells and or the tumor complex. To
test this hypothesis, we used a murine model in which human
primary medulloblastoma (from subjects MB1277 and MB 1323)
were orthotopically propagated in the right cerebellar cortex. Ten
days after tumor establishment, mice were injected with T
lymphocytes or sham injected into the right (ipsilateral) caudate
nucleus. The injected T lymphocytes had a predominantly CD8-
positive population. Six days later, the tumors were removed and
examined by IHC for human CD3. Figure 2A shows that human
CD3-positive cells could be detected only in animals receiving
human T lymphocytes but not sham injected animals, suggesting
that primary medulloblastoma can trigger T lymphocyte migra-
tion from distant sites in the brain. To confirm T cell migration in
the Daoy human medulloblastoma model by bioluminescence
imaging, we injected luciferase-expressing human T cells into the
left caudate nucleus of mice with established, 10 day old Daoy
tumors in their contralateral caudate nucleus. T lymphocytes
migrated within the brain to contralateral tumors in all
experimental animals as shown in Figures 2B and 2C. Immuno-
histochemistry using human CD3-specific antibodies demonstrat-
ed columns of T lymphocytes migrating along the corpus
callosum, the only solid connection between both hemispheres,
and their clustering at the tumor periphery as well as within the
tumor itself (Figure 2D).
T lymphocytes that migrated to tumors in vivo fail to
migrate to tumor cells in vitro
T lymphocyte migration has generally been attributed to a
response to a chemokine gradient generated by chemokine-
secreting tumors. [28–32]. To examine the mechanism whereby
tumor cells are attracting T lymphocytes, we performed a series of
ex vivo transwell studies. Surprisingly, the same T lymphocytes that
avidly migrated in vivo to tumor deposits failed to migrate in vitro
when exposed to supernatants from cultures of the primary
medulloblastoma samples in short-term culture or to the
medulloblastoma cell line, Daoy (Figure 3A). Failure to migrate
could not be explained by adverse in vitro cell culture conditions,
since positive control B-lymphoblastoid cell line (LCL) superna-
tants induced brisk migration of T lymphocytes in vitro.A s
anticipated, no migration was seen in response to media alone.
To determine the mechanism responsible for failure of T
lymphocyte migration to tumor cells in vitro, we characterized the
chemokine profile of the tumor cells using a semiquantitative
chemokine profiling system. We then used flow-cytometric analysis
of T lymphocytes to determine their expression of the chemokine
counter-receptors. Daoy medulloblastoma cells had a distinct
chemokine signature, producing MCP-1; Gro-a; MIF; IL-8; Serpin
E1; and IL-6 (Figure 3B and Figure S1). All 7 primary tumors
secreted MIF, 4 tumors secreted IL-8, 3 tumors secreted MIP-1a
and only one tumor secreted IL-13 and IL12. MB1277 and
MB1323 secreted only MIF, the only molecule common to all
samples tested. T lymphocytes, however, only expressed substantial
levels of CXCR3, CXCR4 and CCR3 on their surface; CXCR1,
CXCR2 and CCR1 were expressed by less than 10% of cells
Figure 1. T lymphocytes consistently infiltrate primary medulloblastoma. Representative photomicrographs of CD3 IHC of human primary
medulloblastoma demonstrating variable degrees of infiltration: modest perivascular pattern (#1%; 15 of 20 tumors), moderate perivascular
infiltration with varying degrees of parenchymal spill (.1–10%; 4 of 20 tumors) and uniform heavy perivascular and parenchymal infiltration (.10%;
1 of 20 tumors). Similarly, tumor sections from the same subjects were stained for CD8 using IHC and showed similar degrees and patterns of
infiltration. Magnification x100.
doi:10.1371/journal.pone.0020267.g001
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PLoS ONE | www.plosone.org 2 May 2011 | Volume 6 | Issue 5 | e20267Figure 2. T lymphocytes migrate and localize to distant tumor deposits in the brain. (A) IHC for human CD3 in explants of tumors,
propagated in the right cerebellum from subjects MB1277 and MB1323, 6 days after human T lymphocytes were injected into the ipsilateral caudate
nucleus (x200). (B) Experimental tumors were established from the medulloblastoma cell line, Daoy, in the right caudate nucleus of SCID mice. Ten
days later firefly luciferase-expressing T lymphocytes were stereotactically injected into the contralateral (left) caudate. T lymphocytes migrated
within the brain to contralateral tumors in all experimental animals (n=5) as judged by bioluminescence imaging. (C) The migration pattern of T
lymphocytes was monitored over predefined gates placed over the left and right frontal lobes. Quantitative bioluminescence imaging indicated T
lymphocyte efflux into the contralateral tumor gate in all experimental animals. (D) Immunohistochemistry for human CD3 performed on a subset of
animals confirmed clustering of T lymphocytes at the tumor site.
doi:10.1371/journal.pone.0020267.g002
Tumor/Endothelium Crosstalk Attracts T Cells
PLoS ONE | www.plosone.org 3 May 2011 | Volume 6 | Issue 5 | e20267(Figure 3C). Hence T lymphocytes lacked measurable chemokine
receptors that are cognate for the chemokines the tumor cells
produce, explaining the observed lack of in vitro migration.
Tumor cells trigger the secretion of the potent chemo-
attractant: Regulated upon Activation, Normal T-cell
Expressed, and Secreted (RANTES) from the endothelium
and induce avid T-cell migration in vitro
The discrepancy between the in vivo and in vitro migration of T
lymphocytes, led us to hypothesize that successful migration
occurred in vivo because primary tumor cells triggered a
secondary, tumor-stroma derived, chemokine signal that was
successfully recognized by T lymphocytes. Growing evidence
supports an essential and complex role for the vascular
endothelium in cancer biology and progression. [25] In
particular, crosstalk between endothelial and tumor cells was
shown to regulate tumor progression and resistance to anti-cancer
therapies in various manners depending on the tumor type. [25–
27] We therefore cocultured tumor cells with murine brain tumor
endothelial cells (bEND.3) to more closely mimic our in vivo
system. We characterized changes in the chemokine profile
during the period of coculture. Supernatants from Daoy and
bEND.3 cocultures contained a chemokine pattern that was
different from those observed in either cell population alone.
Distinctly, the coculture contained large amounts of RANTES,
which were detectable after 48 hours and reached a plateau after
6 days (Figure 4A and Figure S2). This effect was not contact-
Figure 3. T lymphocytes that migrated to tumors in vivo fail to migrate to tumor cells in vitro. (A) T lymphocytes were placed in the upper
wells of 4 mm transwell systems. Supernatants from primary medulloblastoma cells (MB1277 and MB1323), Daoy medulloblastoma cells, LCLs and
unconditioned media were placed in the lower well. While LCL supernatants induced brisk T lymphocyte migration (p,0.001), their migration
towards Daoy supernatants was comparable to that of media only. (B) Chemokine signatures of Daoy and 7 primary medulloblastoma culture
supernatants. (C) Flowcytometry of CD4 and CD8 subsets to study the chemokine receptor expression pattern on T lymphocytes. No chemokine
receptors corresponding to tumor-derived chemokines were detectable on the cell surface. This explained the failure of supernatants from tumor
cells to attract T lymphocytes ex vivo.
doi:10.1371/journal.pone.0020267.g003
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cells were separated by a 0.2 mm pore membrane. Other
chemokines/chemo-attractant molecules that were present in
low concentrations but progressively increased in coculture
included C5-a, MCP-1, Gro-a, sICAM-1, MIF and IL-8. These
molecules, unlike RANTES, were also present at low concentra-
Figure 4. Supernatant from medulloblastoma and brain endothelial cell coculture induces avid T lymphocyte migration in vitro
through the induction of RANTES. (A) Semiquantitative measurement of chemokines using protein profiler membranes showed that while
RANTES was near undetectable in supernatant from bEND.3 or in supernatant from Daoy grown for 6 days, its secretion substantially increased as
early as 48 hours of Daoy and bEND.3 coculture and rapidly increased over time to plateau after 6 days. (B) ELISA for murine RANTES quantitatively
confirmed these results and determined that RANTES is endothelium- rather than tumor-derived. (C) Supernatants from Daoy and b.END.3 coculture
system were used to test T lymphocyte migration in transwell systems. In contrast to supernatants from tumor or that from brain endothelium cells,
supernatants of tumor and endothelium cocultures induced avid migration of T lymphocytes. (D) Using 1,000 ng/mL and 10,000 ng/mL of RANTES
blocking Ab decreased T lymphocyte migration by 30 and 60 %, respectively (p=0.03 and 0.007, respectively) confirming the dominant role of
RANTES in triggering T lymphocyte migration. Blocking Ab to IL8 and MIF up to 10,000 ng/mL failed to counteract the migration to Daoy and bEND.3
coculture supernatants.
doi:10.1371/journal.pone.0020267.g004
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proportion to the degree of confluency of the Daoy cells.
Next, we determined the source of RANTES in the tumor/
endothelium coculture. At the protein level, murine RANTES
shows 88% homology with human RANTES and exhibits species
cross reactivity on human and mouse cells. [33,34] The RANTES
probe in our chemokine protein multiplex assay cross reacted with
both human and murine RANTES. Therefore we determined
whether the RANTES we detected was human- (tumor cell) or
murine- (endothelial cell) derived by re-measuring RANTES levels
using a murine-specific ELISA. Our species-specific assay showed
high activity of murine endothelium-derived protein but not of its
human counterpart (Figure 4B).
To test if the signal derived from the tumor–endothelial
coculture system attracts T lymphocytes: we collected these
supernatants daily and used them to test T lymphocyte migration
in a transwell system. Culture supernatants from tumor or
endothelial cells alone grown for six days induced minimal
migration of T lymphocytes. By contrast, we observed avid
migration of T lymphocytes when we used supernatants from the
combination of tumor and endothelial cells. (Figure 4C) The
degree of migration paralleled the concentration of RANTES
protein in the supernatants, becoming detectable after 48 hours of
coculture, and progressively increasing to plateau from day 6. To
determine the role of RANTES and other chemokines in inducing
T lymphocyte migration, we incubated 6 day Daoy and bEND.3
coculture supernatants with RANTES-blocking antibody (Ab) or
IL8- or MIF-blocking Ab, as controls. RANTES Ab blocked the
migration to the coculture supernatant by up to 60% while control
IL8- and MIF-Ab failed to do so (Figure 4D).
Tumor-derived ‘‘Macrophage Migration Inhibitory Factor
(MIF)’’ is the primary tumor chemokine signal triggering
RANTES release from the endothelium
Our chemokine array analysis had revealed that all 7 primary
medulloblastomas and Daoy secreted MIF, and that neither
secreted RANTES (Figure 3B and Figure S1 and S2). To
investigate if MIF acts directly on endothelial cells to release
RANTES, we incubated bEND.3 cells with increasing concentra-
tions of recombinant human MIF (rhMIF), a molecule that is 90–
98% homologous to murine MIF and biologically active on both
human and murine cells. [14,35] Using a murine ELISA, we
observed that supernatants from such cultures contained
RANTES in a MIF-dose-dependent concentration (Figure 5A).
We thus concluded that, in vitro, MIF can directly trigger the
release of RANTES from endothelial cells.
To further confirm in vivo that MIF was necessary for triggering
RANTES production from endothelial cells, we generated MIF-
knock down (KD) Daoy medulloblastoma cells using a retroviral
vector encoding a MIF-specific shRNA. The MIF-specific shRNA
reduced MIF production by 80% in comparison to the parental
cell line (Figure 5B). To corroborate the link between expression of
MIF and RANTES in vivo, we established tumors from the
parental cell line Daoy, from MIF-KD Daoy cells, and from IL-8-
KD Daoy cells (control). RNA was extracted from the tumor and
the adjacent brain matter analyzed by qPCR for RANTES and
two housekeeping genes (GAPDH and b-actin). While IL-8-KD
Daoy tumors induced murine RANTES RNA levels similar to
those of un-manipulated Daoy, MIF-KD Daoy tumor RNA
showed a 38-fold decrease in RANTES expression compared to
parental Daoy tumors. Control gene expression was similar among
Daoy, MIF-KD and IL8-KD Daoy (Figure 5C). Hence, MIF-KD
tumor cells failed to induce murine RANTES in vivo; confirming
that MIF released by tumor cells is the primary chemokine that
triggers the release of RANTES from endothelial cells.
Finally, we studied, in vivo, the requirement of the MIF-
RANTES axis for T lymphocyte migration to the tumor site. Ten
days after establishing tumors derived from MIF-KD Daoy in the
right caudate nucleus of mice, we stereotactically injected firefly
luciferase-expressing T lymphocytes into the left caudate nucleus.
Histological examination of a subset of animals showed that Daoy
and MIF-KD Daoy xenografts had similar volumes (not shown).
Firefly luciferase-expressing T lymphocytes that migrated briskly
to established Daoy tumors failed to migrate to the contra-lateral
MIF-KD Daoy tumors (Figure 5D). IHC of tumors explanted
from the right hemispheres confirmed the absence of T
lymphocytes.
Discussion
We have shown that the interaction between medulloblastoma
cells and their associated endothelium triggers T lymphocyte
migration into the tumor microenvironment. Medulloblastoma
cells constitutively release the chemokine MIF which itself cannot
recruit T lymphocytes, but triggers the release of a second
chemokine, RANTES, from endothelial cells in the tumor stroma.
This in turn attracts T lymphocytes since they express RANTES-
cognate chemokine receptors. [36] We thus demonstrate that
‘cross-talk’ between the tumor cells and endothelium creates a
chemotactic gradient triggering T lymphocyte migration to the
tumor microenvironment.
Leukocyte migration to disease sites has been extensively studied
in research models of inflammation and autoimmune diseases.
[14–24] These studies have shown that in the presence of
chemokines induced by the pathological process, leukocytes are
activated and directed out of the vasculature into the sites of tissue
injury. The role of cells in the tumor microenvironment, including
endothelial cells, in creating a gradient for leukocyte migration is
well characterized in these models. [14–24] In contrast, little is
known about their role in the process of T lymphocyte migration
in the context of malignancies. Decoding such mechanistic events
would increase our understanding of T lymphocyte migration to
the tumor microenvironment.
Our work describes a previously uncharacterized dimension to
the phenomenon of intra-parenchymal T lymphocyte migration
that involves a third party, the tumor endothelium. Coculture of
medulloblastoma tumor cells and endothelial cells resulted in a
new chemokine signature dominated by the progressive secretion
of endothelium- rather than tumor-derived RANTES, a strong T
lymphocyte chemo-attractant that is not produced by either cell
type culture alone. Since CCR3 is strongly expressed on migrating
T lymphocytes, we suspected that RANTES was the major
chemoattractant of T lymphocytes to the tumor microenviron-
ment. This was confirmed by the observed inhibition of T
lymphocyte migration after RANTES neutralization.
While both MIF and IL-8 were secreted by the majority of
primary tumors as well as by Daoy cell line, T lymphocytes
migrated to two different experimental tumors derived from
primary cells that secreted only MIF. MIF, a chemokine-like
inflammatory mediator, triggers leukocyte recruitment by binding
to CXCR2 and CXCR4 [37,38]. While CXCR4 was expressed
on T lymphocytes tested in this study, its chemotactic effect is
contingent on forming heterodimers with cell surface-expressed
CD74. [39] The latter was undetectable on the T lymphocytes,
explaining their failure to migrate to MIF in transwell systems. We
further demonstrated that knocking down MIF but not IL-8 in the
tumor cell line results in failure of T lymphocytes to migrate to
Tumor/Endothelium Crosstalk Attracts T Cells
PLoS ONE | www.plosone.org 6 May 2011 | Volume 6 | Issue 5 | e20267Figure 5. The primary medulloblastoma chemokine signal triggering the release of RANTES is mediated by MIF. (A) Increasing
concentrations of exogenous recombinant human (rh)MIF added to 72 hour cultures of bEND.3 cells induced the release of murine RANTES in a
rhMIF-dose-dependent manner. (B) Supernatants from cell cultures analyzed for the production of MIF showing that Daoy cells transduced with a
MIF-specific shRNA encoding construct (MIF-KD Daoy) secreted substantially less MIF (,20%) compared to the parental Daoy cell line. (C) RNA was
extracted from tumors established from Daoy, MIF-KD Daoy and IL-8-KD Daoy and analyzed for the presence of RANTES as well as GAPDH and b-Actin
(controls). While IL-8-KD Daoy tumors showed minimal inhibition of RANTES RNA (4.8 fold decrease), MIF-KD Daoy tumor RNA showed a 38 fold
decrease in expression compared to the parental cell line Daoy. Both house-keeping genes were minimally altered. (D) MIF-KD Daoy cells induced
similar size tumors in comparison to parental Daoy cells but failed to induce T lymphocyte migration in vivo.
doi:10.1371/journal.pone.0020267.g005
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established tumors showed substantial inhibition of RANTES in
MIF-KD explants. This indicates that MIF, derived from tumor
cells, is responsible for RANTES production by endothelial cells
and subsequently, T lymphocyte migration.
The vast majority of human chemokine molecules have a high
degree of amino acid sequence homology to their murine
counterpart. [14,34,35,40–44] These molecules exhibit complete
cross-species activity on human and mouse cells but, depending on
the antibody used for testing, could be immunologically distinct.
[14,35,40,41] We thus took advantage of the xenogenic setup to
determine the source of RANTES using both human and murine
specific ELISA that employ antibodies specific to a non-conserved
epitope on the molecule. To exclude the possibility that the
observed induction of RANTES was due to a xenogeneic effect,
we repeated the same experiment using co-culture of Daoy cells
with primary Human Brain Microvascular Endothelial cells
(HBMEC) and obtained similar results to those obtained with
murine endothelial cells. (Figure S3) We thus propose a model of T
lymphocyte migration as a result of the interaction between the
tumor and endothelium as outlined in Figure 6.
Rubin et al. has shown previously that endothelial cells attract
medulloblastoma cells through the CXCL12/CXCR4 axis and
that this interaction is critical for tumor establishment. [45] Our
results now indicate that the tumor cell/endothelial cell interac-
tions results in recruitment of T lymphocytes, which have the
potential to further promote tumor growth. Indeed, on examining
a number of primary medulloblastomas, we found an infiltrate of
T lymphocytes that was typically perivascular with various degrees
of parenchymal involvement. This finding has implication for how
tumor niches are formed and suggests a ‘domino effect’ in which
the recruitment of one cell type triggers the recruitment of
another.
Thus, interventions that inhibit the effects of MIF (to counteract
the primary tumor-derived signal) [38] and or RANTES (to
counteract the endothelium derived signal), or block their cognate
receptors could possibly offset tumor growth by altering the tumor-
induced niche. Conversely, the innate avidity of T lymphocytes to
the tumor microenvironment could be exploited therapeutically by
redirecting their specificity towards tumor-restricted antigens.
Studies to test these therapeutic interventions by our group are
currently underway.
In summary, we have shown that the crosstalk between tumor
and endothelial cells creates an effective chemotactic gradient
triggering the in vivo migration of T lymphocyte to the tumor
microenvironment. Manipulation or exploitation of these interac-
tions may be of benefit to tumor control.
Materials and Methods
Blood donors, primary tumor cells and cell lines
Studies were performed on Baylor College of Medicine IRB-
approved protocols and informed written consent was obtained
from all donors. The medulloblastoma line Daoy was purchased
from ATCC (Manassas, VA). All cell lines were grown in DMEM
(Invitrogen, Carlsbad, CA) with 10% fetal calf serum (FCS;
HyClone, Logan, UT), with 2 mM GlutaMAX-I, 1.5 g/L sodium
bicarbonate 0.1 mmol/L and 1.0 mmol/L sodium pyruvate
(Invitrogen). T lymphocytes derived from PBMCs were activated
on CD3 antibody-coated plates and were expanded in IL-2
(100U/mL)-containing RPMI 1640 with 10% FCS and 2 mM
GlutaMAX-I. Primary Human Brain Microvascular Endothelial
Cells (HBMECs) were obtained from CellScience (Carlsbad, CA)
and were cultured in Endothelial Cell Medium, obtained from the
same vendor.
Tumor tissues were processed aseptically, and primary cell
cultures were initiated using the supplemented DMEM. Cells were
used within three days of plating.
Retroviral construct, retrovirus production and
transduction of T lymphocytes
We used an SFG retroviral vector containing an eGFP-firefly
luciferase fusion gene in order to generate firefly luciferase
expressing T lymphocytes for the in vivo study. [46,47] To produce
retroviral supernatant, 293T lymphoctyes were cotransfected with
retroviral vector containing plasmid, pEQ.PAM-E plasmid
encoding the sequence for MoMLV gag-pol, and plasmid
pMEVSVg containing the sequence for VSV-G, using GeneJuice
transfection reagent (EMD Biosciences, San Diego, CA) [40].
Supernatants containing the retrovirus were collected 48 and
72 hours later. VSV-G pseudotyped viral particles were used to
transduce the FLYRD18 producer cell line for the production of
RD114 pseudotyped viral particles [41].
T lymphocytes were transduced with retroviral vectors as
described. [46,47] Briefly, peripheral blood mononuclear cells
(PBMC) were isolated by Lymphoprep gradient centrifugation.
5610
5 PBMC per well of a 24-well plate were activated with
OKT3 (OrthoBiotech, Raritan, NJ) at a final concentration of
1 mg/mL. On day 2, recombinant human IL-2 (Chiron,
Emmeryville, CA) was added at a final concentration of
50 units/mL, and on day 3 cells were harvested for retroviral
transduction. For transduction, we pre-coated a non-tissue culture
treated 24-well plate with a recombinant fibronectin fragment (FN
CH-296; Retronectin; Takara Shuzo, Otsu, Japan). Wells were
washed with phosphate-buffered saline (PBS; Sigma, St. Louis,
MO) and incubated twice for 30 minutes with retrovirus.
Subsequently, 3610
5 T lymphocytes per well were transduced
with retrovirus in the presence of 50 units IL-2 per mL. After 48–
72 hours, cells were removed and expanded in the presence of 50–
100 units IL-2 per mL for 10–15 days prior to use.
Orthotopic xenogenic SCID mouse model of
medulloblastoma
All animal experiments were conducted on a protocol AN3949
approved by the Baylor College of Medicine Institutional Animal
Care and Use Committee (IACUC). Recipient NOD-SCID mice
were purchased from Taconic (C.B-Igh-1
b/IcrTac-Prkdc
scid; FOX
CHASE CB-17 SCID
TM ICR; Taconic, Hudson, NY). Male 9
week to 12 week-old mice were anesthetized with rapid sequence
Figure 6. Proposed Model of T Lymphocyte Migration to
Medulloblastoma Cells. MIF secreted by medulloblastoma cells
induce endothelial cells to produce RANTES, which triggers the
migration of T lymphocytes to the tumor microenvironment.
doi:10.1371/journal.pone.0020267.g006
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an intraperitoneal injection of 225–240 mg/kg AvertinH solution
and then maintained on isofluorane by inhalation throughout the
procedure. The head was shaved, then the mice were immobilized
in a Cunningham
TM Mouse/Neonatal Rat Adaptor (Stoelting,
Wood Dale, IL) stereotactic apparatus fitted into an E15600 Lab
Standard Stereotactic Instrument (Stoelting), then scrubbed with
1% povidone-iodine. A 10 mm skin incision was made along the
midline. The tip of a 31G K inch needle mounted on a Hamilton
syringe (Hamilton, Reno, NV) served as the reference point. A
1 mm burr-hole was drilled into the skull, 1 mm anterior to and
2 mm to the right of the bregma. Daoy cells (2.5610
5 in 2.5 mL)
were injected 3 mm deep to the bregma, corresponding to the
center of the right caudate nucleus over 5 minutes. The needle was
left in place for 3 minutes, to avoid tumor cell extrusion, and then
withdrawn over 5 minutes. Ten days after tumor cell injection,
animals received 2610
6 eGFP.Firefly-luciferase-expressing T
lymphocytes in 2.5 mL at the same tumor coordinates in the
contralateral caudate nucleus (Bregma +1 mm anterior; +2m mt o
the left of the midline, +3 mm deep). The incision was closed with
2–3 interrupted 7.0 EthiconH sutures (Ethicon, Inc. Somerville,
NJ). A subcutaneous injection of 0.03–0.1 mg/kg buprenorphine
(BuprenexH RBH, Hull, England) was given for pain control. The
primary medulloblastoma xenograft model was described previ-
ously. [48]
Bioluminescence imaging
Isofluorane anesthetized animals were imaged using the IVISH
system (IVIS, Xenogen Corp., Alameda, CA) 10 minutes after
150 mg/kg D-luciferin (Xenogen) was injected intraperitoneally.
[49] The photons emitted from luciferase-expressing cells within
the animal body and transmitted through the tissue were
quantified using "Living Image", a software program provided
by the same manufacturer. A pseudo-color image representing
light intensity (blue least intense and red most intense) was
generated and superimposed over the grayscale reference image.
Animals were imaged after injections daily. They were regularly
examined for any neurological deficits, weight loss or signs of stress
and euthanized according to pre-set criteria, in accordance the
Baylor College of Medicine’s Center for Comparative Medicine
guidelines.
Immunohistochemistry (IHC)
Mice were euthanized by CO2 inhalation and fixed with intra-
cardiac perfusion of 4% paraformaldehyde. The brain tissue was
post-fixed overnight and embedded in paraffin, and histology was
performed on 10-mm serial horizontal sections. Tissue sections
were stained by a standard hematoxylin and eosin technique.
Human CD3 expression in T lymphocytes was detected by human
CD immunohistochemistry. The same methodology was used to
stain primary medulloblastoma samples.
Transwell migration assays
T lymphocyte migration towards tumor chemokines was
measured in vitro through the use of a transwell migration assay.
Firefly luciferase expressing T lymphocytes (1610
5 in 100 mL
serum-free media) were placed in the top insert chamber of 4mm
transwell migration plate (Corning Inc., Corning, NY). The lower
chamber was filled with 600 mL of either control medium,
supernatant from various cell lines, or medium conditioned with
a specific chemokine. After a 3 hour incubation at 37uC, the
medium from the lower chamber was collected and biolumines-
cence was measured for 30 seconds after 15 second incubation
with 150 mg D-luciferin (3010 Luminometer, BD Biosciences, San
jose, CA).
Analysis of chemokine production
The detection and quantification of chemokine production from
tumor cells and endothelial cells was done using a cytokine array
kit (Human and Murine Proteome Profiler
TM array, R&D
Systems, Minneapolis, MN). Supernatant from tumor cells alone,
endothelial cells alone, and both cell lines in co-culture were
collected at various time points and tested for 36 different
chemokines per the manufacturer’s instructions.
Supernatant from the co-culture of endothelial cell lines and
tumor cell lines were collected at various time points and tested by
cytokine-specific ELISA per the manufacturer’s instructions (R&D
Systems, Minneapolis, MN).
Flowcytometry
For all flowcytometric analyses, a FACScalibur instrument (BD,
Becton Dickinson, Mountain View, CA) and CellQuest software
(BD) were used. Data analysis was done on .10,000 events; in all
cases negative controls included isotype antibodies. Cells were
washed once with PBS containing 2% FBS and 0.1% sodium
azide (Sigma; FACS buffer) prior to addition of antibodies. After
15 to 30 minutes of incubation at 4oC in the dark the cells were
washed once and fixed in 0.5% paraformaldehyde/FACS buffer
prior to analysis. T lymphocytes were analyzed with anti-CD8
FITC, -CD4 PE, and -CD3 PerCP as well as the chemokine
receptors, CXCR1, CXCR2, CXCR3, CXCR4, CCR1, CCR2,
CCR3, CCR4, CCR5, CCR6, CCR7 and CD74. All monoclonal
antibodies were obtained from BD Biosciences, Palo Alto, CA.
Generation of knockdown medulloblastoma lines
MIF knockdown (KD) and IL-8-KD Daoy cells were generated
by transducing Daoy cells with RD114 pseudotyped retroviral
vectors encoding shRNAs for MIF or IL8 (pRS shRNA; 4 shRNAs
per target gene; Origene; Rockville, MD). Transduced cells were
selected with puromycin, and MIF or IL-8 production was
measured by ELISA (R&D Systems, Minneapolis, MN). Daoy cell
lines with the greatest decreased of MIF (81% of controls) or IL-8
(78% of controls) production were used in subsequent experi-
ments.
RNA extraction and analysis
RNA was isolated from explanted Daoy and KD Daoy
xenografts. Total RNA concentrations were measured using the
Nanodrop 1000 spectrophotometer (Nanodrop Scientific, Wil-
mington, DE). RNA integrity was checked in electrophoresis using
2% agarose gel with 6% formaldehyde. The human and murine
chemokine and chemokine receptor arrays were performed by
SABiosciences Inc (Frederick, MD) using PAHS-022 (human) and
PAMM-022 (mouse) chemokine and receptor arrays.
Statistical analysis
For the bioluminescence experiments, intensity signals were log-
transformed and summarized using mean 6 SD at baseline and
multiple subsequent time points for each group of mice. Changes
in intensity of signal from baseline at each time point were
calculated and compared using paired t-tests or Wilcoxon signed-
ranks test.
Supporting Information
Figure S1 A protein profiler system was used to
characterize the chemokine pattern specific to Daoy
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signature, producing MCP-1; Gro-a; MIF; IL-8; Serpin
E1; and IL-6 [quantified in Figure 3B].
(TIF)
Figure S2 Chemokine protein profiler membranes
showed that while RANTES was near undetectable in
supernatant from bEND.3 or in supernatant from Daoy,
its secretion substantially increased as early as 48 hours
of Daoy and bEND.3 coculture and rapidly increased
over time to plateau after 6 days. Other chemokines/
chemo-attractant molecules that were present in a low concentra-
tion but progressively increased in coculture were also present at
low concentrations in Daoy only supernatants and increased to
higher levels in proportion to the degree of confluency of the Daoy
cells.
(TIF)
Figure S3 In Daoy and HBMEC cocultures, RANTES
appeared anew on days 2–4 of co-culture and its levels
increased rapidly 6 days after co-culture, as determined
by a human RANTES-specific ELISA.
(TIF)
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